China is fast becoming a major player in the global pharmaceutical and biotech industries. Once focused primarily on generic and me-too drugs, Chinese companies are now making headlines with innovative breakthroughs in oncology and gene therapy. Foreign investors are taking notice, pouring billions into partnerships and research projects across the country. But can China maintain this momentum — or will political pressure and consumer skepticism slow things down?
Skip Montreux and Dez Morgan explore how China’s pharmaceutical and biotech sectors are reshaping the global healthcare landscape. They trace the industry’s evolution from state-run factories to world-class R&D centers, discuss the surge in foreign investment, and introduce key players like Akeso Biopharma. Along the way, they also unpack some of the challenges that may lie ahead for this fast-growing industry.
Their conversation is a great learning resource if you want to build your English listening comprehension skills and expand your business vocabulary. Key points of their discussion include:
The difference between pharmaceuticals and biotech — and where they overlap.The rise of Chinese firms like Akeso Biopharma and their potential to rival Western Big Pharma.Key challenges facing the sector, including domestic reputation issues and foreign policy risk.
